Stock HAVN HAVN LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials HAVN Life Sciences Inc.

Equities

HAVN

CA4196213058

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 14:12:37 2023-11-09 EST 		5-day change 1st Jan Change
0.03 CAD -.--% Intraday chart for HAVN Life Sciences Inc. +20.00% -.--%
2023 HAVN Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
2023 HAVN Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI

Valuation

Fiscal Period: April 2021 2022
Capitalization 1 75.26 10.7
Enterprise Value (EV) 1 66.31 10.03
P/E ratio -1.38 x -0.4 x
Yield - -
Capitalization / Revenue - 38,689,550 x
EV / Revenue - 36,279,535 x
EV / EBITDA -4,601,144 x -1,338,029 x
EV / FCF 28,906,449 x -3,166,324 x
FCF Yield 0% -0%
Price to Book 5.79 x 3.41 x
Nbr of stocks (in thousands) 3,533 5,094
Reference price 2 21.30 2.100
Announcement Date 21-08-30 22-08-29
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: April 2020 2021 2022
Net sales - - 0.2765
EBITDA - -14.41 -7.496
EBIT 1 -0.4933 -18.99 -7.978
Operating Margin - - -2,885.5%
Earnings before Tax (EBT) 1 -0.4869 -30.38 -22.44
Net income 1 -0.4869 -30.38 -22.44
Net margin - - -8,117.81%
EPS 2 -4.680 -15.46 -5.245
Free Cash Flow - 2.294 -3.168
FCF margin - - -1,145.79%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 20-06-09 21-08-30 22-08-29
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: April 2020 2021 2022
Net Debt 1 - - -
Net Cash position 1 1.62 8.95 0.67
Leverage (Debt/EBITDA) - - -
Free Cash Flow - 2.29 -3.17
ROE (net income / shareholders' equity) - -402% -275%
ROA (Net income/ Total Assets) - -147% -54.5%
Assets 1 - 20.71 41.19
Book Value Per Share 2 3.460 3.680 0.6200
Cash Flow per Share 2 2.940 2.620 0.2100
Capex - 0.03 0.1
Capex / Sales - - 37.28%
Announcement Date 20-06-09 21-08-30 22-08-29
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HAVN LIFE SCIENCES INC. Stock HAVN Life Sciences Inc.
-.--% 627K
MODERNA, INC. Stock Moderna, Inc.
+23.98% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.49% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.95% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.64% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.46% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.91% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.09% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.73% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HAVN Stock
  4. Financials HAVN Life Sciences Inc.